Affimed EBITDA Margin 2014-2024 | AFMDQ
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Affimed (AFMDQ) over the last 10 years. The current EBITDA margin for Affimed as of September 30, 2024 is .
| Affimed EBITDA Margin Historical Data |
| Date |
TTM Revenue |
TTM EBITDA |
EBITDA Margin |
| 2024-09-30 |
$0.00B |
$-0.07B |
0.00% |
| 2024-06-30 |
$0.00B |
$-0.08B |
-4150.00% |
| 2024-03-31 |
$0.00B |
$-0.10B |
-2475.00% |
| 2023-12-31 |
$0.01B |
$-0.11B |
-1255.56% |
| 2023-09-30 |
$0.02B |
$-0.12B |
-571.43% |
| 2023-06-30 |
$0.03B |
$-0.11B |
-332.35% |
| 2023-03-31 |
$0.04B |
$-0.10B |
-260.00% |
| 2022-12-31 |
$0.04B |
$-0.09B |
-204.55% |
| 2022-09-30 |
$0.04B |
$-0.09B |
-202.27% |
| 2022-06-30 |
$0.04B |
$-0.09B |
-235.90% |
| 2022-03-31 |
$0.04B |
$-0.09B |
-206.98% |
| 2021-12-31 |
$0.05B |
$-0.08B |
-156.25% |
| 2021-09-30 |
$0.05B |
$-0.06B |
-127.66% |
| 2021-06-30 |
$0.05B |
$-0.04B |
-83.67% |
| 2021-03-31 |
$0.04B |
$-0.03B |
-82.50% |
| 2020-12-31 |
$0.03B |
$-0.04B |
-121.88% |
| 2020-09-30 |
$0.03B |
$-0.04B |
-152.00% |
| 2020-06-30 |
$0.02B |
$-0.05B |
-320.00% |
| 2020-03-31 |
$0.02B |
$-0.05B |
-276.47% |
| 2019-12-31 |
$0.02B |
$-0.04B |
-145.83% |
| 2019-09-30 |
$0.05B |
$-0.01B |
-23.40% |
| 2019-06-30 |
$0.05B |
$-0.01B |
-26.67% |
| 2019-03-31 |
$0.04B |
$-0.01B |
-30.00% |
| 2018-12-31 |
$0.03B |
$-0.02B |
-82.14% |
| 2018-09-30 |
$0.00B |
$-0.04B |
-2100.00% |
| 2018-06-30 |
$0.00B |
$-0.04B |
-1200.00% |
| 2018-03-31 |
$0.00B |
$-0.03B |
-800.00% |
| 2017-12-31 |
$0.00B |
$-0.03B |
-1000.00% |
| 2017-09-30 |
$0.00B |
$-0.03B |
-1000.00% |
| 2017-06-30 |
$0.00B |
$-0.03B |
-1100.00% |
| 2017-03-31 |
$0.00B |
$-0.04B |
-875.00% |
| 2016-12-31 |
$0.01B |
$-0.04B |
-583.33% |
| 2016-09-30 |
$0.01B |
$-0.04B |
-514.29% |
| 2016-06-30 |
$0.01B |
$-0.03B |
-471.43% |
| 2016-03-31 |
$0.01B |
$-0.03B |
-428.57% |
| 2015-12-31 |
$0.01B |
$-0.02B |
-300.00% |
| 2015-09-30 |
$0.01B |
$-0.02B |
-266.67% |
| 2015-06-30 |
$0.01B |
$-0.01B |
-128.57% |
| 2015-03-31 |
$0.01B |
$0.00B |
-33.33% |
| 2014-12-31 |
$0.00B |
$0.00B |
25.00% |
| 2014-09-30 |
$0.00B |
$0.00B |
25.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.001B |
$0.009B |
|
Affimed N.V is a clinical stage biopharmaceutical company. It is engaged in developing single and combination therapies to treat cancers. The company's product pipeline consists of AFM13, AFM24, AFM26, AFM11 and AMV564 which are in clinical stage. Affimed N.V, formerly known as Affimed Therapeutics B.V., is based in Heidelberg, Germany.
|
